Ad Code

Responsive Advertisement

Enhanced CAR T cell therapy offers new strategy for lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

from Latest Science News -- ScienceDaily https://ift.tt/nEibsMy

Post a Comment

0 Comments

Close Menu